Puma Biotech (PBYI) Tops Q3 EPS by 10c; Offers FY23 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Puma Biotechnology Reports Third Quarter 2023 Financial Results
November 2, 2023 4:05 PM EDTLOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2023. Unless otherwise stated, all comparisons are for the third quarter of 2023 compared to the third quarter of 2022.
Product revenue, net consists entirely of sales revenue from NERLYNX®, Pumas first commercial product. Product revenue, net in the third quarter of 2023 was $51.6 million, compared to $54.3 million in the third quarter of 2022. Product revenue, net in the first nine months of 2023 was $149.9 million, compared to $146.3 million in the first nine months of 2022.
Based... More
